Updated on 8 September 2026
NANOCOMBO project: exploring opportunities in drug repurposing associated with multi-drug combination
CEO at THERIOPHARM
About
Drug combination is a very powerful approach to design and tailor efficient treatment . Our nanodrop technology have the same size than a coronavirus and can be loaded with targeting synthons (RGD peptide, for example).
We are looking for academics/SMEs interested in exploring with us our NANOCOMBO approach. Our technology is suitable for any administration route in any therapeutic field.
We currently develop a drug repurposing approach applied to cancer solid tumor treatment (Glioblastoma) in murine preclinical models.
We seek for experts in organoids, PDX models, PK/PD, imaging, digital twins , to extend the strategy to other types of cancer.
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Attached files
Organisation
Similar opportunities
Project cooperation
Organ on chips, organoids and other NAMs for biomedical research
- Partner seeks Consortium/Coordinator
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Joude Cachoux
Business Development Manager, PharmD, MPH at Leitat Technological Center
Barcelona, Spain
Project cooperation
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Evangelia-Mantelena Makri
Project Manager / Biomedical Scientist at Cloudpharm P.C
Athens, Greece
Project cooperation
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Wolfgang Fecke
Executive Director at Association of European Cancer Leagues (ECL)
Brussels, Belgium